BioLineRx (NASDAQ:BLRX) Upgraded to Strong-Buy at Jones Trading

BioLineRx (NASDAQ:BLRX) was upgraded by Jones Trading from a “hold” rating to a “strong-buy” rating in a report issued on Friday, Marketbeat Ratings reports.

Several other analysts have also commented on BLRX. HC Wainwright reissued a “buy” rating on shares of BioLineRx in a research report on Wednesday, May 28th. Wall Street Zen assumed coverage on shares of BioLineRx in a research note on Sunday, May 18th. They set a “sell” rating for the company.

BioLineRx Trading Up 2.9%

Shares of NASDAQ BLRX traded up $0.12 during mid-day trading on Friday, reaching $4.22. The company had a trading volume of 334,484 shares, compared to its average volume of 218,279. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. The stock has a market cap of $14.05 million, a price-to-earnings ratio of -0.48 and a beta of 1.15. The business’s 50-day moving average is $3.18 and its 200-day moving average is $5.32. BioLineRx has a 52 week low of $2.30 and a 52 week high of $35.60.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, May 27th. The biotechnology company reported $1.39 EPS for the quarter, topping the consensus estimate of ($0.84) by $2.23. BioLineRx had a negative return on equity of 163.37% and a negative net margin of 90.57%. The company had revenue of $11.75 million for the quarter, compared to the consensus estimate of $7.72 million. Equities analysts expect that BioLineRx will post -5.8 earnings per share for the current year.

Institutional Investors Weigh In On BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. Highbridge Capital Management LLC purchased a new stake in BioLineRx Ltd. (NASDAQ:BLRX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned about 50.50% of BioLineRx as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.